We thank Halabi et al for their expert comment on our editorial,1 which referred to their previous article.2 Although we agree that, from a statistical perspective, there is reason to believe that progression-free survival (PFS) may represent an adequate surrogate endpoint for overall survival (OS), we do not agree that this statistical association is sufficient to officially accept PFS as the surrogate endpoint for OS. As noted in the IMPACT study, which examined sipuleucel-T immunotherapy for patients with castration-resistant prostate cancer, an improved OS was not found to be associated with an improved PFS.3 Therefore, it would be difficult to justify the role of PFS as a surrogate endpoint for OS if the 2 do not always correlate. Furthermore, pharmaceutical drugs may often perpetuate OS, independent of disease progression. Although it may be stipulated that Prentice's third criterion4 is considered a “high bar,” we argue that it should be so. Our intention is not to completely reject the possibility of attributing a higher importance to PFS when interpreting results from ongoing and future clinical trials, but rather we believe that the advancements made in the treatment of metastatic renal cell carcinoma after the era of targeted therapy have made it possible for physicians and patients to look forward to real improvements in both OS and quality of life, and not merely to an increased time to disease progression. No specific funding was disclosed. The authors made no disclosures. Andreas Becker, MD Department of Urology University Hospital Hamburg-Eppendorf; Martini-Clinic Prostate Cancer Center Hamburg, Germany Christian Eichelberg, MD Department of Urology Caritas-St. Josef Medical Center University of Regensburg Regensburg, Germany Maxine Sun, BS Cancer Prognostics and Health Outcomes Unit Department of Urology University of Montreal Health Centre Montreal, Quebec, Canada